中国癌症杂志 ›› 2015, Vol. 25 ›› Issue (10): 796-801.doi: 10.3969/j.issn.1007-3969.2015.10.007

• 论著 • 上一篇    下一篇

伴PET/CT骨髓弥漫性糖代谢增高的淋巴瘤患者骨髓浸润情况及相关因素分析

顾史洋,邹善华,李 锋,王伟光,袁 玲,季丽莉,程韵枫   

  1. 复旦大学附属中山医院血液科,上海 200032
  • 出版日期:2015-10-30 发布日期:2015-12-17
  • 通信作者: 李 锋 E-mail:li.feng@zs-hospital.sh.cn
  • 基金资助:
    上海市科委资助项目(12DZ1930103)。

Bone marrow infiltration and clinical features in lymphoma patients with diffused high bone marrow glucose uptake by 18F-FDG PET/CT

GU Shiyang, ZOU Shanhua, LI Feng, WANG Weiguang, YUAN Ling, JI Lili, CHENG Yunfeng   

  1. Department of Hematology, Zhongshan Hospital of Shanghai Medical College, Fudan University, Shanghai 200032, China
  • Published:2015-10-30 Online:2015-12-17
  • Contact: LI Feng E-mail: li.feng@zs-hospital.sh.cn

摘要: 背景与目的:正电子发射计算机断层显像技术(positron emission tomography-computed tomography,PET/CT)在淋巴瘤的诊断、治疗和随访中发挥着越来越重要的作用。该研究旨在探索PET/CT显示骨髓弥漫性糖代谢异常增高的淋巴瘤患者骨髓有无浸润、淋巴瘤病理类型以及其他临床特点。方法:回顾性分析复旦大学附属中山医院62例经病理确诊为淋巴瘤且PET/CT显示骨髓弥漫性糖代谢增高患者的临床资料、病理以及PET/CT详细数据,并行统计学分析。结果:PET/CT显示有骨髓弥漫性糖代谢异常增高的患者,其淋巴瘤病理类型分布与国内所报道各亚型淋巴瘤发病比例基本一致;侵袭性与惰性淋巴瘤之间[标准摄取值(standard uptake value,SUV)分别为8.43与5.38,P=0.048]、有或无B症状之间(SUV分别为8.30与5.72,P=0.033)、有或无骨髓浸润之间(SUV分别为8.78与6.96,P=0.020),SUV的差异均有统计学意义。32例(51.6%)患者经骨髓活检病理证实骨髓受累。骨髓受累者其淋巴瘤病理类型的分布上与未受累者差异有统计学意义(P=0.001);骨髓受累者套细胞淋巴瘤、结内边缘区B细胞淋巴瘤、伯基特淋巴瘤和间变大细胞淋巴瘤者比例较高,而骨髓未受累者弥漫大B细胞淋巴瘤、外周T细胞淋巴瘤、肠病相关性T细胞淋巴瘤和NK/T细胞淋巴瘤(鼻型)者比例较高。PET/CT骨摄取假阳性可能与发热、贫血等有关。结论:PET/CT骨髓弥漫性糖代谢异常增高虽然对临床诊疗有一定的提示,但应结合PET/CT骨糖代谢异常增高的特点、患者的临床因素及病理亚型综合分析,以减少误诊与漏诊,更精确地指导分期及治疗。

关键词: 正电子发射计算机断层显像技术, 骨髓弥漫性糖代谢增高, 淋巴瘤, 骨髓浸润

Abstract: Background and purpose: Positron emission tomography-computed tomography (PET/CT) is playing an increasingly important role in the diagnosis, therapy and follow-up of lymphoma patients. This study aimed to explore clinical and pathological features and bone marrow infiltration status in lymphoma patients with diffused high bone marrow glucose uptake on 18F-FDG PET/CT. Methods: It was a retrospective study. Bone marrow infiltration status, pathological and clinical data from 62 cases of pathologically diagnosed lymphoma and diffused high bone marrow glucose uptake were analyzed. Results: Distribution of histopathological subtype in those cases was in accordance with that in previously reported Chinese lymphoma patients. Significant difference was demonstrated in standard uptake value (SUV) between patients with aggressive and indolent histopathological subtypes (8.43 vs 5.38, P=0.048), patients with and without B symptoms (8.30 vs 5.72, P=0.033), and patients with and without bone marrow infiltration (8.78 vs 6.96, P=0.020). 32 patients were diagnosed as “bone marrow infiltration” by bone marrow biopsy. There was significant difference in histopathological subtype distribution between patients with and without bone marrow infiltration (P=0.001). In patients with bone marrow infiltration, there were higher proportions of mantle cell lymphoma, nodal marginal zone B cell lymphoma, Burkitt’s lymphoma and anaplastic large cell lymphoma. In contrast, patients without bone marrow infiltration suffered more from diffuse large B-cell lymphoma, peripheral T cell lymphoma, enteropathic T cell lymphoma and extranodal NK/T-cell lymphoma (nasal type). False positive results in bone marrow glucose uptake may be caused by fever or anemia. Conclusion: Diffused high bone marrow glucose uptake on 18F-FDG PET/CT should be evaluated in combination with the uptake values, clinical features and histological subtypes, to minimize the misdiagnosis and to better guide staging and therapy of lymphoma.

Key words: Positron emission tomography-computed tomography, Diffused high bone marrow glucose uptake, Lymphoma, Bone marrow infiltration